Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• The landscape of multiple sclerosis (MS) treatment has significantly evolved with a doubling of available disease-modifying therapies (DMTs).
• Thirteen distinct DMTs are now approved, each demonstrating varied efficacy and safety profiles based on clinical trials and real-world data.
• The expanded therapeutic options necessitate a nuanced understanding of individual treatment benefits and risks for both clinicians and patients.

Purpose of the Study:

• To review and discuss risk stratification and mitigation strategies for currently available disease-modifying therapies (DMTs) in multiple sclerosis (MS).
• To emphasize the importance of an individualized treatment approach considering medication efficacy, side effects, patient preferences, and comorbidities.

Main Methods:

• This is a review article, synthesizing existing data on DMTs for MS.
• The review focuses on risk-benefit analyses and comparative effectiveness of various MS therapies.
• Strategies for patient risk stratification and management are discussed based on current evidence.

Main Results:

• Multiple sclerosis (MS) now has 13 approved disease-modifying therapies (DMTs), presenting a wider array of treatment choices.
• Each DMT exhibits a unique profile of efficacy, safety, and potential side effects.
• Factors such as patient comorbidities and preferences are critical in selecting the optimal DMT.

Conclusions:

• An individualized approach to multiple sclerosis (MS) treatment is essential due to the diverse profiles of available disease-modifying therapies (DMTs).
• Effective management requires careful consideration of medication efficacy, side-effect profiles, and patient-specific factors.
• Risk stratification and tailored mitigation strategies are crucial for optimizing DMT use in MS care.